Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625

Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625

BackgroundProgressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625, a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma, but pseudoresponse likely limited enhancement-based survival prognostication in T1 non-progressors. We aimed to determine...

Full description

Bibliographic Details
Main Authors: Jerrold L. Boxerman, Bradley S. Snyder, Daniel P. Barboriak, Kathleen M. Schmainda
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
recurrent glioblastoma
bevacizumab
pseudoresponse
DSC-MRI
(CBV) cerebral blood volume
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1061502/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1061502/full

Similar Items